tirzepatide surpass cvot SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized SURPASS-CVOT: Tirzepatide better than dulagluti...
Pay in 4 interest-free payments of $7.09 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 20 - Oct 25






















:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)



![살을 빼는 열쇠, GLP-1 호르몬 [이슈 픽 쌤과 함께]](https://i.ytimg.com/vi/eqv3B8UlfkQ/maxresdefault.jpg)


